ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain

ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain
CANNANNEW REPORT

GREENWOOD VILLAGE, Colo. & NEW YORK–(BUSINESS WIRE)–ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology. This trial is evaluating Nantheia™ A1002N5S for Opioid Sparing in the treatment of participants with Radiculopathic Pain Syndromes. This trial is being conducted at NYU Grossman School of Medicine, led by Stephen Ross, MD, Associate Professor of Psychiatry. Funding for this trial is from the National Institute of Drug Abuse (NIDA), with additional support from ANANDA. The NYU Grossman School of Medicine is No. 2 in the nation for research in the 2022 U.S. News & World Report “Best Graduate Schools” rankings. “We are excited to get this important trial underway and expanding research on therapeutic alternatives to opioid pharmacotherapies,” said Dr. Ross. “This research protocol creates an opportunity for the possible development of evidence-based CBD medicinal products to reduce opioid intake and pain.” “We are very pleased to be continuing our collaboration with NYU Grossman School of Medicine. We are impressed by the scientific rigor and professionalism of the NYU team in putting a cutting-edge program in place to test the efficacy of this very promising drug,” said Sohail R. Zaidi, ANANDA’s CEO. “The initiation of patient enrollment in this study is an important step in efforts to provide patients with Radiculopathic Pain with an alternative to the use of Opioids for the management of pain.” This is a randomized, double-blind, placebo-controlled trial with 40 participants receiving four months of treatment with Nantheia™ A1002N5S, or placebo with a follow-up after 2 months. The primary efficacy outcome is a change in opioid maintenance dose from baseline to the end of the treatment period.…

Excerpt only …
READ MORE BELOW
Source : ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.